In PC-3 xenograft-bearing mice, oral axitinib at 25 mg/kg reduced tumor growth relative to vehicle, and combination with fractionated radiation produced greater suppression than either treatment alone. A separate PC-3/DU145 experiment found similar growth suppression when axitinib was given 1 h before or after radiation. These findings concern xenograft efficacy and treatment order, not pharmacokinetics or clinical benefit. [2]
PC-3 xenograft growth with axitinib and radiation
Animal study · PC-3 human prostate carcinoma xenografts in male NCr nu/nu mice. [2]
By day 10, axitinib alone and radiation alone each reduced tumor volume relative to vehicle controls. The combination produced smaller mean tumor volumes than either single treatment.
Conditions shared by the study groups
- Route
- Oral gavage
- Treatment course
- Two treatment weeks; Figure 1A follows tumor growth through day 11.
- Vehicle
- 0.5% carboxymethylcellulose drug carrier.
- Axitinib alone
- Model: PC-3 xenografts in male NCr nu/nu mice.
- Frequency: Daily on the treatment days marked in Figure 1A: days 0–4 and 7–11.
- Reported limits: No exact numerical effect size extracted from the plotted curves.
- Axitinib plus fractionated radiation
- Model: PC-3 xenografts in male NCr nu/nu mice.
- Frequency: Axitinib on Figure 1A treatment days, 1 h before each radiation fraction; radiation 2 Gy/fraction, 5 fractions/week.
- Reported limits: No exact numerical effect size extracted from the plotted curves.
Methods and source locations
Compound reported in the paper: Axitinib; Compound label in the paper: AG-013736
Compound-level published research; no batch equivalence or Adooq validation claimed.
Methods: Tumor and Animal Models, Treatments, Statistical Analysis; Results: Tumor Progression is Significantly Inhibited; Figure 1A
Tumor volume relative to vehicle and single-treatment groups: Tumor-volume measurements three times weekly; Figure 1A reports means with SE for 7–12 tumors/group. Significance threshold P ≤ 0.05; exact comparison-specific P values not given here. — Results: Tumor Progression is Significantly Inhibited, first paragraph; Figure 1A caption; Statistical Analysis
Axitinib alone · Figure 1A and caption; Methods: Treatments; first Results paragraph
Axitinib plus fractionated radiation · Figure 1A and caption; Methods: Treatments; first Results paragraph
Daily axitinib–radiation order in prostate xenografts
Animal study · PC-3 and DU145 human prostate carcinoma xenografts in male NCr nu/nu mice. [2]
Giving axitinib 1 h before or 1 h after each radiation fraction produced nearly identical tumor-growth suppression in both models; the study did not establish an advantage for either order.
Conditions shared by the study groups
- Route
- Oral gavage
- Treatment course
- Approximately 2 weeks.
- Vehicle
- 0.5% carboxymethylcellulose drug carrier.
- Axitinib before radiation
- Model: PC-3 and DU145 human prostate carcinoma xenografts in male NCr nu/nu mice.
- Frequency: Axitinib 1 h before each daily 2-Gy radiation fraction; radiation 5 days/week.
- Reported limits: Axitinib dose not explicitly restated for Figure 3; no dose borrowed from Figure 1.
- Axitinib after radiation
- Model: PC-3 and DU145 human prostate carcinoma xenografts in male NCr nu/nu mice.
- Frequency: Axitinib 1 h after each daily 2-Gy radiation fraction; radiation 5 days/week.
- Reported limits: Axitinib dose not explicitly restated for Figure 3; no dose borrowed from Figure 1.
Methods and source locations
Compound reported in the paper: Axitinib; Compound label in the paper: AG-013736
Compound-level published research; no batch equivalence or Adooq validation claimed.
Methods: Treatments; Results: Altered Order of Treatment does not Modify Tumor Growth or Vessel Spacing; Figure 3A–B and caption
Tumor growth for pre- versus post-irradiation axitinib: Longitudinal tumor-volume comparison; 8–12 tumors/group; plotted means with SE. — Results: Altered Order of Treatment does not Modify Tumor Growth or Vessel Spacing, first paragraph; Figure 3A–B and caption
Axitinib before radiation · Methods: Treatments; Figure 3A–B and caption; Results: Altered Order of Treatment
Axitinib after radiation · Methods: Treatments; Figure 3A–B and caption; Results: Altered Order of Treatment